Emocog

About Emocog

Emocog, a digital healthcare company established in Seoul, South Korea, is focused on developing therapeutic solutions for cognitive impairment. Founded in 2021 by Dr. Jun Young Lee, a professor at Seoul National University's Department of Psychiatry, and Yoo Hun Noh, a former anatomy professor at Chung-Ang University, the company was born from their recognition that the preclinical stage of dementia, mild cognitive impairment (MCI), was not being adequately managed. Their collective expertise in dementia, aging research, and brain function improvement forms the foundation of the company's approach.

The company develops and provides software as a medical device (SaaMD) for the assessment and treatment of cognitive decline. Emocog’s business strategy involves forging partnerships with health screening centers and insurance providers to create an integrated healthcare model for cognitive screening. This ecosystem allows for early detection and management, starting with screening, referral for advanced diagnostics if needed, and subsequent treatment with their proprietary software. The firm targets neurological and psychiatric disorders such as dementia, Parkinson's disease, and ADHD.

Emocog's product suite addresses the full spectrum of dementia care. "Memory Cock" (기억콕콕) is a web-based software that provides a quick, 5-minute cognitive health check-up accessible on mobile devices. For patients diagnosed with MCI, "Cogthera" offers personalized, AI-powered cognitive training through a user-friendly, voice-based interface, enabling treatment from home. This digital therapeutic digitizes years of dementia research to provide tailored interventions. In 2023, Cogthera was designated as an innovative medical device by the Ministry of Food and Drug Safety and also received its CE mark for entry into the European market. The company is also expanding its portfolio to include solutions for learning disabilities in children and adolescents, such as dyslexia and dyscalculia, through a partnership with Happymind.

Since its founding, Emocog has secured significant investment from major corporations and venture capitalists, including Naver D2SF, StoneBridge Ventures, Kakao Ventures, and Shinhan Venture Investment. A notable Series B funding round in late 2024 raised approximately $15 million to accelerate research, development, and global market expansion, particularly in Europe and the United States.